Pulmonology Lasers Market - Regional Analysis
North America Market Insights
The North America pulmonology lasers market is projected to account for a leading share of 37% by the end of 2037. The growth is driven by the escalating COPD and the government's supportive policies. The U.S. and Canada are steering owing to increased demand of minimally invasive laser treatment of diseases like COPD, lung cancer, and severe asthma. In the U.S., the National Institutes of Health (NIH) raised its funding of pulmonology lasers to 8% of the federal healthcare budget, to USD 4 billion in 2023. The provincial health departments, especially in Ontario and Alberta, have expanded funding by 17% to meet the expanded access to patients. This government spending and rising clinical usage are setting North America up for prolonged pulmonology laser development and procedural expansion.
The U.S. pulmonology lasers market is on the threshold of strong growth due to the ageing population and increased rates of COPD and lung cancer. On the federal level, the National Institutes of Health (NIH) has designated USD 4 billion to pulmonology lasers in 2023. In the meantime, the Medicare expenditures related to pulmonology laser procedures increased by 14% in 2020-2024, as the changes in the reimbursement policy provided more elderly patients with access to the procedure. Such federal initiatives are being augmented by a growing clinical acceptance of less invasive laser treatments at tertiary care hospitals and specialty clinics. This expansion is also sponsored by the Centers for Disease Control and Prevention (CDC) and the Agency for Healthcare Research and Quality (AHRQ), which run national respiratory health programs for early diagnosis and intervention. Taken together, clinical integration, changes in policies, and governmental funding are defining a healthy growth trend in the pulmonology lasers market in the United States through 2037.
Asia Pacific Market Insights
The pulmonology lasers market in Asia-Pacific will grow at a healthy rate in the coming years, owing to the increasing cases of respiratory diseases, growing healthcare facilities, and excellent governmental support. The key factors leading to the increase in the burden of pulmonary conditions include rapid urbanization, growing levels of pollution, and a high rate of smoking in countries such as China and India. According to the Ministry of Health and Family Welfare, India has a market size of massive adoptions and increasing investments, where over 2 million patients will be treated and more than USD 1.6 billion will be spent on pulmonology lasers in 2023. Malaysia and South Korea demonstrate stable growth by means of reimbursement and increasing numbers of patients. The national initiatives on lung health, the public and private hospital expansion, and the subsidized access to advanced laser therapies to rural populations support this growth too.
By 2037, India is expected to have the highest CAGR in the Asia-Pacific pulmonology lasers market due to increasing cases of chronic respiratory disorders and massive governmental spending on healthcare facilities and infrastructure. As published by the Ministry of Health and Family Welfare (MoHFW), government expenditure on pulmonology lasers in India has rapidly increased by over 16% in the past few years. Central Drugs Standard Control Organization (CDSCO) has also been prompt in approvals of laser-based technologies, which have encouraged their use in government hospitals. Demand is also pushed by the high levels of air pollution in India, which is associated with increased cases of COPD and asthma. Moreover, the Indian Council of Medical Research is strongly supportive, and public-private partnerships are also increasing, which guarantees further growth.
